

WHEN IT COMES TO AIDS,
TOO MANY STAY SILENT.
IT'S TIME TO
TALK CURE

A PERSONAL INTRODUCTION

RESEARCH FOUNDATION TO
CURE A+DS

RFTCA.org/donate + kambiz.shekdar@RFTCA.org



Dear Friend,

Ten years ago, the world saw the first breakthrough in curing AIDS, when stem cells were used to cure a man of the virus. This success points to other promising developments that could be within our reach. However, over the last decade, a second person has yet to be cured, and significant challenges and work remain to create a universal cure. At Research Foundation to Cure AIDS (RFTCA), we are using the latest stem cell research to activate a cutting-edge cellular engineering cure method.

To date, efforts to address AIDS are largely focused on prevention and treatment. While these initiatives are commendable, we must also strive to make room for cutting-edge cell therapy technologies.

Much more can and must be done. Cell therapy technology holds great promise in curing AIDS, but this innovative approach now needs champions. We believe there are people out there who would support the research and development for a universal cure —if only they knew it could be possible. Many people have never heard of the one and only man cured of AIDS, and more still don't realize that it is a roadmap to create a universal cure. Stigma also keeps many would-be supporters at bay. While this is a very sensitive and personal issue, it is always those who care most about a disease who are needed as champions to drive the leading edge of medical innovation and philanthropy forward.

Here's where you come in: If you or anyone you know would like to contribute to curing AIDS, we would be grateful to discuss your interest and have your support to raise awareness and funding. Please share this Personal Introduction with anyone you know who may want to join in our mission.

Thank you for your time and consideration. We look forward to hearing from you.

Sincerely,

Kambiz Shekdar, PhD
President and Founder of RFTCA



A CURE FOR AIDS IS FINALLY WITHIN REACH—WE NEED YOU TO MAKE IT HAPPEN

When you think of AIDS, you probably think of drug cocktails and prevention efforts. You may think that the virus is under control. Many people do. But the truth is, AIDS kills millions of people each year. And think of the huge ripple effect; millions with the virus needlessly suffer, along with their loved ones, family, and society.

There are many advocacy groups that focus on prevention, education, and treatment. Research Foundation to Cure AIDS (**RFTCA**) is designed to complement those efforts with a rigorous scientific study on a brand new concept: **cure**.


Stem cell biology has come a long way. With genome editing, modification of DNA, and personalized medicine, stem cell therapy holds a power to treat and cure disease in ways never before seen. Cellular biologist Kambiz Shekdar, the founder and president of RFTCA, invented a biotechnology that manipulates stem cells and could create curative cells—thus curing AIDS.

This cure method was formed partly from the famous case of “the Berlin patient,” the first and only man cured of AIDS. He was cured in 2007 with a stem cell transplant and remains free of the virus to this day. With innovative stem cell therapies and using this case as a blueprint, we forge forward to create a cost-effective and practical way to bring a cure to everyone. We'll do it with the best minds, equipment, and science.

We've reached that time in history where it's possible to fundamentally change how we think about AIDS, from treating it—to curing it.

STAND BEHIND A CURE AND HELP
FREE THE WORLD OF THIS VIRUS

Let's Cure AIDS®
Cure+®



THE SCIENCE BEHIND THE CURE

Kambiz invented the biotechnology that manipulates cells, called Chromovert® technology, originally for purposes unassociated with AIDS. But now he sees it can be used to create curative cells that are HIV-resistant.

Although it is not a commonly known fact, there are millions of people who are naturally resistant to HIV. Their cells simply reject the virus. A physician put this knowledge to practice in April 2007 in the case of Timothy Ray Brown, widely known as “the Berlin patient.” Brown’s physician transplanted HIV-resistant cells into his immune system. These cells created a new, HIV-resistant immune system in his body—curing him of AIDS.

This case points us to the type of stem cells that are curative. Now, we need a cell therapy method that can turn certain cells in the body into ones that reject the virus. Several cellular engineering technologies may play a role in curing AIDS, and we support all initiatives with charitable components. The biotechnology invented by Kambiz has surpassed all other technologies in a diverse range of other applications and also holds strong promise in the endeavor to find a cure for AIDS.

“ I had no idea the biotechnology I invented many years ago could someday be used to cure AIDS. Now that we know its capabilities, we won’t stop until we reach the cure. ”

-Kambiz Shekdar, President and Founder of the RFTCA



HERE'S HOW A CURE COULD WORK

1

The doctor draws a patient's blood.

2

Stem cells are isolated and sent to a biotechnology center.

3



Scientists use cellular engineering technologies to mold the patient's stem cells into curative stem cells.

4

Cells are grown and when there are enough, they are shipped back to the doctor's office to be reimplanted into the patient.

5

The newly curative stems cells would flourish and give rise to a new, HIV-resistant immune system, curing the patient of AIDS.



THE PEOPLE AND PASSION BEHIND THE CURE

RFTCA was formed by Kambiz Shekdar, PhD, a cellular biologist who invented a biotechnology that puts innovative stem cell therapy to practice. Once he realized his technology may hold the key to a cure for AIDS, he answered an irrepressible calling to rid the world of a disease that has plagued people for decades.

RFTCA is an alliance of leaders set up to raise awareness and funding, unite selected stakeholders, and act as a think tank to innovate new models of science, medicine, economics, and health care. RFTCA's fundamental objective is to develop a cure for AIDS which is accessible and affordable for those in need worldwide. This cure represents a major paradigm shift from preventing and treating AIDS with drugs to curing it with cellular therapy.

RFTCA partners include individuals from:

Community Research Initiative

Columbia University Medical Center/
New York Presbyterian Hospital

The Rockefeller University

Global Emerging Pathogens
Treatment Consortium (GET)

Morrison & Foerster LLP

Christopher Street Financial

Jonathan Marder and
Company Inc.

Stellenbosch University
(Capetown, South Africa)

Chromocell Corporation

AIDS Healthcare Foundation

Ology Research Group

Havas Health Plus

Board members of RFTCA:



KAMBIZ SHEKDAR, PhD
President and Founder,
Formerly Chief Scientific
Officer at Chromocell
Corporation



CHARLES KERR, Esq.
Former Partner at
Morrison & Foerster



ALLISON CERASO
President and
Chief Experience Officer at
Havas Health Plus



PATRICIA MORRIS
Director of Biomedical R&D,
Senior Scientist Emerita,
Population Council; Investigator,
The Rockefeller University



CHRISTIAN KOPFLI, Esq.
Co-founder and CEO of
Chromocell Corporation



**JESSE ROBERT
LOVEJOY, Esq.**
Principal,
J.R. Lovejoy & Co.



**ALI HEMMATI-
BRIVANLOU, PhD**
Head of Laboratory
and Professor at The
Rockefeller University



KAREN HAGBERG, Esq.
Partner,
Morrison & Foerster

Friends of RFTCA:

Akinola Abayomi
Shruti Adhar
Stephen Adler
Jennyfer Ambe
Bruce Anderson
Penny Arcade
Joey Arias
Linda Arnsbarger
Dale Atkins
Holly Atkinson
Sergio Baratad
Bob Barbero
Thomas Bark
Debbie Beckwith
Oded Ben-Horin
Robert Benjamin
Paul Bennett
Noble Black
Becca Bressler
Nancy Burson
Charles Busch
Guillermo Chacon
Scot & Patrick Chaitoo
Malika Cosme
Ellie Covan
Alan Cumming
Drew Davis
Jim Davis
Machine Dazzle
Flotilla de Barge
Olga Dedova
Dario de Martino
Lloyd DesBrisay

Franco diLuzio
Kevin Dolan
Tricia Donegan
Brian Downey
Sacha Dunas
Brent Nicholson Earle
Chinedu Echeruo
JoyceLyn Elders
Matthew Ellis
Van Ellis
Sue Evans
Andrew Fanelli
Jerry Feeney
Daryl Ferrara
Colette Ferris
Avram Finkelstein
Jacob Fishbein
Vanessa Fitzgerald &
Andrea Aranguren
Jeanne Fleming
Josh Ford
Alessandra Gagliardi
Robert Galinsky
Patrik Gallineaux
Amin El Gamal
Vallejo Gantner
Maria Gotsch
Logan Gray
Barry Greene
Michael Griffiths
Eric Grossman
Jane Gunnison
Scott Hammer

Tyler Hancock
Amanda Harmon
Corey Harris &
Peter D'Orsaneo Tom Hart
Bill Harvey
Jennifer Hatch
John Hemphill
Pamela Herron
Pati Hertling
Jean Marc Houmard
Nathanael Holly
Brian Howard
Becky Howland
James Hough &
Argie Bucot
David Hubschman &
Cologero Salvo
Lynn Humphreys
Colin Jacobsen
Eric Jacobsen
Heiko Jessen
Blanding Jones
Kenneth & Esther
Kashkin
Dave Kaufman
Sandy Kaufman
Joel Kehle &
Anthony Carro
Joan Kim
Benjamin Kimitch
Maggie Kneip
Marlene LaLota

Don Landry
Carl & Jazmin
Latemendi
Bob Laterza
Patrick Laterza
Reagan Leibowitz
Keith Levy
Hui Liu
Marian Liu
Christopher Livoti
Carlos Lopez
Brooke Ludi
Timothy Lunceford
Daniel Jack Lyons
Jonathon Marder
Jay Margolis
Steven Marian
Sebastian Martinek
Richard Massey
Maggie Mayo
Maedhbh McCullagh
& Jonathan Jacobs
Michael McGrail
JJ McKay
Meghan McLean
Steven Love
Menendez
Mark Mitten
Daniel Mitura
Julie Miwa
Dominic Mondavi
Tom Monson
Felix Morelo

Hal Moskowitz &
John Murphy
Michael Musto
Julie Atlas Muz
Hannah Olivet
Joseph O'Neill
Nikola Pavelic
Larry Peoples
Denaka Perry
Peppermint
Anne Radice
Lutz Rath
Jessie Redden
Remmelt Reigersman
Lisa Reilly
Jessica Reinhart
Paige Rice
Steve Rodriguez
Ryan Roerman
Tamar Rogoff
Josh Rosenzweig
Claude Salzberger &
Joseph Lavine
Jason Samuel
Marcus Sands
Nullah Sarkar
Paul Saso
Dennis Sawchuk
Dan Scaglione
Jenny Schlenzka
Kristin Schrupf
Ross Schwartz
John Sefakis

Lucy Sexton
Keshni Sharma
Terri Shieh-Newton
Virna Smiraldi
Monica Rose Song
Lauren Sparks
Wendy Sporman
Andre Springer
Bruce Steinberg
Jill & Bill Steinberg
Joseph Sulzbach
Dyan Summers
Jeanine Tappen
Joey Terrill
Stephen Thau
Tigger!
Timorell
Elina Tirulnik
Genaldri Tjahjadi
Basil Twist
Sherry Vine
Milton Wainberg
Michael Wakefield
Todd Warner
Michael Weinstein
Michael Weiss
Ashley Willis &
Kate Bridges
Brandon Wise
Karina Yazdanbakhsh
Jia Jia Ye
Steven Zehentner
Jie Zhou

BE A PART OF HISTORY. HELP US FUND A CURE

The RFTCA is proposing a game-changing method to cure a devastating disease—with the potential to change history and help millions. It seeks greater access to bold thinkers and significant resources to complement the magnitude of their endeavor.

Your donation will be used carefully and purposefully, and is tax-deductible. Here are examples of what your donation may go toward in the laboratory the RFTCA has access to.



\$1,000,000

Adapt preliminary results to fresh human stem cells

Using laboratory cells, we have already obtained preliminary results to create cells that mimic those used to treat “the Berlin patient.” Funding up to this level will allow us to hit our immediate scientific goal, which represents the pivotal research milestone of adapting these preliminary results to freshly isolated human stem cells.

\$300,000

Support a research team member’s work for a year

Salary and experiments for one full-time research technician or scientist in the laboratory. If you donate this amount, a research technician will be supported in your name, or in memory or honor of a person of your choosing.

\$1,000 to \$100,000

Support individual experiments and laboratory equipment

Basic scientific supplies and equipment, from cell culture petri dishes to centrifuges, microscopes and capital equipment; and supports day-to-day experiments and work performed in the lab.



WILL YOU BE A PART OF THE HISTORIC EFFORT TO CURE AIDS?



To set up a call or meeting with Kambiz Shekdar, the President and Founder of RFTCA, and the developer of Chromovert® technology, email him at kambiz.shekdar@RFTCA.org.



RFTCA is a not-for-profit corporation exempt from taxation under Section 501(c)3 of the Internal Revenue Code. Donations to RFTCA are tax-deductible to the fullest extent allowable by law. RFTCA has ultimate authority to use contributions made to it in its discretion for purposes consistent with its tax exempt purpose.

WE'RE DONE
IGNORING IT.

WE'RE DONE
HIDING FROM IT.

WE'RE DONE
ACCEPTING THE STATUS QUO.

BECAUSE AS IMPOSSIBLE AS SOME MAY THINK,
ONE THING IS CERTAIN:

CAN'T
SILENCE
A CURE
FOR AIDS



RFTCA.ORG/DONATE